Alicia Marsà
Research Subjects
Alicia Marsà has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Josep Darbà
Department of Economics, Universitat de Barcelona, Barcelona, Spain
10 shared publications Javier Diaz-García
Medical Department, Jazz Pharmaceuticals Iberia, Barcelona, Spain
1 shared publicationM Ascanio
BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL, Barcelona, Spain
1 shared publicationMeritxell Ascanio
Department of Health Economics, BCN Health Economics & Outcomes Research SL, Barcelona, Spain
1 shared publication
Latest Publications
- 8 November 2022
- Published by Springer Nature in PharmacoEconomics
- Vol. 40 (12) , 1143-1158
Economic Implications of Endometriosis: A Review
Endometriosis is a chronic inflammatory disease that can have serious physical and emotional consequences for patients in terms of pain, quality of life, and infertility. Despite affecting about 10% of women, the pathophysiology and economic impact of the disease are not fully understood. This study aimed to review and summarize research articles quantifying the direct and indirect costs of endometriosis in the context of current national and international treatment guidelines. A search including the terms ‘endometriosis’ AND ‘costs’ OR ‘cost of illness’ OR ‘cost analysis’ OR ‘economic burden’ was performed, focusing on studies published between January 2000 and May 2022. Total costs, costs of primary and secondary care, productivity losses, and indirect costs were reported. The medical costs of endometriosis were principally registered in secondary care settings, where surgery was the main cost driver. There was considerable variability of populations and study settings, with the overall direct medical cost range of endometriosis from US$1459 to US$20,239 (2022) per patient per year. An increasing trend has been reported in secondary care costs over time; however, not enough data were available at this time to evaluate inpatient and outpatient costs versus treatment strategies. Similarly, further research is required to evaluate the costs and potential savings associated with new therapies. Numerous studies have evaluated the indirect costs of endometriosis in recent years, finding costs between US$4572 and US$14,079 (2022). Currently, limited data are available on the economic burden of the disease at the patient level.
- 8 November 2022
- Published by Springer Nature in PharmacoEconomics
- Vol. 40 (12) , 1143-1158
Economic Implications of Endometriosis: A Review
Endometriosis is a chronic inflammatory disease that can have serious physical and emotional consequences for patients in terms of pain, quality of life, and infertility. Despite affecting about 10% of women, the pathophysiology and economic impact of the disease are not fully understood. This study aimed to review and summarize research articles quantifying the direct and indirect costs of endometriosis in the context of current national and international treatment guidelines. A search including the terms ‘endometriosis’ AND ‘costs’ OR ‘cost of illness’ OR ‘cost analysis’ OR ‘economic burden’ was performed, focusing on studies published between January 2000 and May 2022. Total costs, costs of primary and secondary care, productivity losses, and indirect costs were reported. The medical costs of endometriosis were principally registered in secondary care settings, where surgery was the main cost driver. There was considerable variability of populations and study settings, with the overall direct medical cost range of endometriosis from US$1459 to US$20,239 (2022) per patient per year. An increasing trend has been reported in secondary care costs over time; however, not enough data were available at this time to evaluate inpatient and outpatient costs versus treatment strategies. Similarly, further research is required to evaluate the costs and potential savings associated with new therapies. Numerous studies have evaluated the indirect costs of endometriosis in recent years, finding costs between US$4572 and US$14,079 (2022). Currently, limited data are available on the economic burden of the disease at the patient level.
- 1 November 2022
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 18 (4) , 285-291
Hospital Incidence and Medical Costs of Female Breast Cancer in Spain: A Retrospective Multicenter Study
Background: Breast cancer is the most prevalent cancer type in women worldwide, causing the greatest number of cancer-related deaths. This study aimed to evaluate the use of healthcare resources associated with female breast cancer in Spain, to analyze trends in hospitalization and death rates, and the related direct medical costs. Methods: A retrospective multicenter study was designed analyzing records of hospital and ambulatory visits of women diagnosed with breast cancer in Spanish hospitals between 1 January 2005 and 31 December 2018. Results: In total, 353,080 admission files were reviewed, mainly inpatient hospital admissions, corresponding to 299,585 individual patients. Median patient age was 59 years, 12.7% of admissions registered the presence of metastatic tumors and 15.7% registered unspecified secondary tumors. Mean in-hospital death rate was 3.0% for patients without a metastatic disease and 10.5% in patients with a metastatic disease, decreasing significantly over the study period. Total age-adjusted hospitalization rate increased between 2005 and 2011, and decreased after 2012. Mean direct medical cost was €3824 per outpatient visit, €3995 per hospital admission up to 3 days and €5001 per hospital admission over 3 days. Admission cost increased in patients with a metastatic disease and in those deceased during the hospitalization. Conclusions: This study supports previous findings regarding the relative increase in breast cancer incidence that could be attributed to the intensive screening, along with the reduction in the death rate. Mean direct medical cost in this study varied greatly with length of stay, presence of metastatic tumors and disease fatality.
- 1 November 2022
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 18 (4) , 285-291
Hospital Incidence and Medical Costs of Female Breast Cancer in Spain: A Retrospective Multicenter Study
Background: Breast cancer is the most prevalent cancer type in women worldwide, causing the greatest number of cancer-related deaths. This study aimed to evaluate the use of healthcare resources associated with female breast cancer in Spain, to analyze trends in hospitalization and death rates, and the related direct medical costs. Methods: A retrospective multicenter study was designed analyzing records of hospital and ambulatory visits of women diagnosed with breast cancer in Spanish hospitals between 1 January 2005 and 31 December 2018. Results: In total, 353,080 admission files were reviewed, mainly inpatient hospital admissions, corresponding to 299,585 individual patients. Median patient age was 59 years, 12.7% of admissions registered the presence of metastatic tumors and 15.7% registered unspecified secondary tumors. Mean in-hospital death rate was 3.0% for patients without a metastatic disease and 10.5% in patients with a metastatic disease, decreasing significantly over the study period. Total age-adjusted hospitalization rate increased between 2005 and 2011, and decreased after 2012. Mean direct medical cost was €3824 per outpatient visit, €3995 per hospital admission up to 3 days and €5001 per hospital admission over 3 days. Admission cost increased in patients with a metastatic disease and in those deceased during the hospitalization. Conclusions: This study supports previous findings regarding the relative increase in breast cancer incidence that could be attributed to the intensive screening, along with the reduction in the death rate. Mean direct medical cost in this study varied greatly with length of stay, presence of metastatic tumors and disease fatality.
- Open Access
- 24 August 2022
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 22 (7) , 1147-1152
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care
Ischemic heart disease (IHD) is the leading global cause of death and is assumed to entail a significant social and economic burden globally. This study aimed to evaluate incidence and mortality tr...
- 24 August 2022
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 22 (7) , 1147-1152
Open AccessBurden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care
Ischemic heart disease (IHD) is the leading global cause of death and is assumed to entail a significant social and economic burden globally. This study aimed to evaluate incidence and mortality tr...
- Open Access
- 9 June 2022
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 769-773
Ambulatory and hospital care of glaucoma in Spain and associated medical costs
This study aimed to analyze the impact of glaucoma in ambulatory centers and hospitals in Spain over the past decade, in terms of incidence and medical costs.Administrative data of glaucoma patient...
- 9 June 2022
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 769-773
Open AccessAmbulatory and hospital care of glaucoma in Spain and associated medical costs
This study aimed to analyze the impact of glaucoma in ambulatory centers and hospitals in Spain over the past decade, in terms of incidence and medical costs.Administrative data of glaucoma patient...
- Open Access
- 14 March 2022
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 381-385
Hospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis
This study aimed to review the characteristics of patients admitted with septic arthritis in Spanish hospitals and to measure the associated direct medical costs.Hospital admission records of patie...
- 14 March 2022
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 381-385
Open AccessHospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis
This study aimed to review the characteristics of patients admitted with septic arthritis in Spanish hospitals and to measure the associated direct medical costs.Hospital admission records of patie...
- 21 February 2022
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 22 (6) , 1-6
Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis
Polycythemia vera (PV) is one of the most common chronic myeloproliferative neoplasms, yet, little data is available on the epidemiology of PV in Spain and the costs of its management. This study aimed to evaluate the hospital incidence and mortality rate of PV in Spain, and to estimate hospital medical costs. Hospital admission records of patients with PV registered between 2005 and 2019 were obtained from a Spanish hospital discharge database and analyzed in a retrospective multicenter study. Admission files of 490 patients were reviewed. Median age was 74 years; patients presented numerous conditions associated to age, namely hypertension, diabetes or anemia. Hospital mortality rate was associated to pulmonary heart disease, respiratory conditions and kidney disease. Most of the files analyzed corresponded to inpatient admissions; hospital incidence decreased over the study period in patients over 60 years. Median admission cost was €5580, increasing in patients deceased during the hospitalization. Admission cost increased significantly between 2006 and 2011. This study provides an evaluation of hospital management and costs of PV in Spain. Future studies should focus on the revision of disease management in the country and measuring total medical costs, which could be higher than global estimations.
- 21 February 2022
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 22 (6) , 1-6
Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis
Polycythemia vera (PV) is one of the most common chronic myeloproliferative neoplasms, yet, little data is available on the epidemiology of PV in Spain and the costs of its management. This study aimed to evaluate the hospital incidence and mortality rate of PV in Spain, and to estimate hospital medical costs. Hospital admission records of patients with PV registered between 2005 and 2019 were obtained from a Spanish hospital discharge database and analyzed in a retrospective multicenter study. Admission files of 490 patients were reviewed. Median age was 74 years; patients presented numerous conditions associated to age, namely hypertension, diabetes or anemia. Hospital mortality rate was associated to pulmonary heart disease, respiratory conditions and kidney disease. Most of the files analyzed corresponded to inpatient admissions; hospital incidence decreased over the study period in patients over 60 years. Median admission cost was €5580, increasing in patients deceased during the hospitalization. Admission cost increased significantly between 2006 and 2011. This study provides an evaluation of hospital management and costs of PV in Spain. Future studies should focus on the revision of disease management in the country and measuring total medical costs, which could be higher than global estimations.
- 19 January 2022
- Published by Elsevier in Value in Health
- Vol. 25 (1) , S137
POSC188 Analysis of Hospital Incidence and Direct Medical Costs of Intrahepatic Cholangiocarcinoma in Spain
- 19 January 2022
- Published by Elsevier in Value in Health
- Vol. 25 (1) , S137
POSC188 Analysis of Hospital Incidence and Direct Medical Costs of Intrahepatic Cholangiocarcinoma in Spain
- Open Access
- 2 November 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (12) , 1477-1484
Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis
This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. Data were extracted from the Sp...
- 2 November 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (12) , 1477-1484
Open AccessEpidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis
This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. Data were extracted from the Sp...
- 21 October 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (12) , 1435-1440
Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis
The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. To this aim...
- 21 October 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (12) , 1435-1440
Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis
The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. To this aim...
- Open Access
- 16 December 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-7
Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources
Background: Neuroendocrine tumours (NETs) are rare malignancies characterised by its capacity to synthesise and secrete monoamines, due to its neuroendocrine origin. Its varied locations and symptoms have traditionally been responsible for extended delays in their diagnosis. The interest of this study was to characterise the patient population diagnosed with NETs in Spain and to revise how the disease is managed, together with the hospitalisation costs of these patients. Methods: The database included records of all patients diagnosed with a NET between 2010 and 2015. Admission records were used to evaluate hospitalisation, disease management data and costs, and single-patient files were used to characterise the population. Results: Nine Thousand One Hundred Twenty patients were diagnosed with a neuroendocrine tumour between 2010 and 2015, with a 2 fold increase in the diagnosis rate over the study period. 42.25% of the patients were females, while 57.75% were males, and mean diagnosis age was 62.58 years (SD = 14.65). Considering all the registered neuroendocrine neoplasms, 46.86% of the patients had malignant well-differentiated NETs, 32.02% had a malignant poorly differentiated neuroendocrine carcinoma and 42.93% of patients developed metastatic NETs. In addition, 18.59% of patients were diagnosed with benign well-differentiated NETs. The most common tumour sites were the bronchus, lung and other sites, including pancreatic tumours; metastasis was found in the liver and distant lymph nodes. Pancreatic resection was the most common surgical procedure utilised in these patients, summing 19% of total expenses, the injection of an unspecified therapeutic substance (including targeted therapies) was registered in 11.40% of admissions, while chemotherapy was registered in only 6.85% of admissions. The annual healthcare cost of NETs was €15,373,961, corresponding to €9092 per patient. Conclusions: The implementation of standard diagnosis procedures should be prioritised, with a focus on the pancreas and lung, and taking into account that 42.93% of the patients develop a metastatic tumour. The presence of comorbidities and multimorbidities should be considered in order to develop more efficient disease management protocols.
- 16 December 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-7
Open AccessExploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources
Background: Neuroendocrine tumours (NETs) are rare malignancies characterised by its capacity to synthesise and secrete monoamines, due to its neuroendocrine origin. Its varied locations and symptoms have traditionally been responsible for extended delays in their diagnosis. The interest of this study was to characterise the patient population diagnosed with NETs in Spain and to revise how the disease is managed, together with the hospitalisation costs of these patients. Methods: The database included records of all patients diagnosed with a NET between 2010 and 2015. Admission records were used to evaluate hospitalisation, disease management data and costs, and single-patient files were used to characterise the population. Results: Nine Thousand One Hundred Twenty patients were diagnosed with a neuroendocrine tumour between 2010 and 2015, with a 2 fold increase in the diagnosis rate over the study period. 42.25% of the patients were females, while 57.75% were males, and mean diagnosis age was 62.58 years (SD = 14.65). Considering all the registered neuroendocrine neoplasms, 46.86% of the patients had malignant well-differentiated NETs, 32.02% had a malignant poorly differentiated neuroendocrine carcinoma and 42.93% of patients developed metastatic NETs. In addition, 18.59% of patients were diagnosed with benign well-differentiated NETs. The most common tumour sites were the bronchus, lung and other sites, including pancreatic tumours; metastasis was found in the liver and distant lymph nodes. Pancreatic resection was the most common surgical procedure utilised in these patients, summing 19% of total expenses, the injection of an unspecified therapeutic substance (including targeted therapies) was registered in 11.40% of admissions, while chemotherapy was registered in only 6.85% of admissions. The annual healthcare cost of NETs was €15,373,961, corresponding to €9092 per patient. Conclusions: The implementation of standard diagnosis procedures should be prioritised, with a focus on the pancreas and lung, and taking into account that 42.93% of the patients develop a metastatic tumour. The presence of comorbidities and multimorbidities should be considered in order to develop more efficient disease management protocols.